243 related articles for article (PubMed ID: 28956328)
1. Current Understanding of PDE10A in the Modulation of Basal Ganglia Circuitry.
Schülke JP; Brandon NJ
Adv Neurobiol; 2017; 17():15-43. PubMed ID: 28956328
[TBL] [Abstract][Full Text] [Related]
2. PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology.
Niccolini F; Mencacci NE; Yousaf T; Rabiner EA; Salpietro V; Pagano G; Balint B; Efthymiou S; Houlden H; Gunn RN; Wood N; Bhatia KP; Politis M
Mov Disord; 2018 Dec; 33(12):1961-1965. PubMed ID: 30345538
[TBL] [Abstract][Full Text] [Related]
3. PDE10A inhibitors: novel therapeutic drugs for schizophrenia.
Kehler J; Nielsen J
Curr Pharm Des; 2011; 17(2):137-50. PubMed ID: 21355834
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase-10A Inverse Changes in Striatopallidal and Striatoentopeduncular Pathways of a Transgenic Mouse Model of
D'Angelo V; Castelli V; Giorgi M; Cardarelli S; Saverioni I; Palumbo F; Bonsi P; Pisani A; Giampà C; Sorge R; Biagioni S; Fusco FR; Sancesario G
J Neurosci; 2017 Feb; 37(8):2112-2124. PubMed ID: 28115486
[TBL] [Abstract][Full Text] [Related]
5. Regulation of Striatal Neuron Activity by Cyclic Nucleotide Signaling and Phosphodiesterase Inhibition: Implications for the Treatment of Parkinson's Disease.
Padovan-Neto FE; West AR
Adv Neurobiol; 2017; 17():257-283. PubMed ID: 28956336
[TBL] [Abstract][Full Text] [Related]
6. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease.
Miller S; Hill Della Puppa G; Reidling J; Marcora E; Thompson LM; Treanor J
J Huntingtons Dis; 2014; 3(4):333-41. PubMed ID: 25575954
[TBL] [Abstract][Full Text] [Related]
7. PDE10A and PDE10A-dependent cAMP catabolism are dysregulated oppositely in striatum and nucleus accumbens after lesion of midbrain dopamine neurons in rat: a key step in parkinsonism physiopathology.
Giorgi M; Melchiorri G; Nuccetelli V; D'Angelo V; Martorana A; Sorge R; Castelli V; Bernardi G; Sancesario G
Neurobiol Dis; 2011 Jul; 43(1):293-303. PubMed ID: 21515371
[TBL] [Abstract][Full Text] [Related]
8. PDE10A inhibitors: an assessment of the current CNS drug discovery landscape.
Chappie T; Humphrey J; Menniti F; Schmidt C
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):458-67. PubMed ID: 19562642
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 10 inhibitors: new disease modifying drugs for Parkinson's disease?
García AM; Redondo M; Martinez A; Gil C
Curr Med Chem; 2014 Apr; 21(10):1171-87. PubMed ID: 24372206
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase 10A Inhibition Improves Cortico-Basal Ganglia Function in Huntington's Disease Models.
Beaumont V; Zhong S; Lin H; Xu W; Bradaia A; Steidl E; Gleyzes M; Wadel K; Buisson B; Padovan-Neto FE; Chakroborty S; Ward KM; Harms JF; Beltran J; Kwan M; Ghavami A; Häggkvist J; Tóth M; Halldin C; Varrone A; Schaab C; Dybowski JN; Elschenbroich S; Lehtimäki K; Heikkinen T; Park L; Rosinski J; Mrzljak L; Lavery D; West AR; Schmidt CJ; Zaleska MM; Munoz-Sanjuan I
Neuron; 2016 Dec; 92(6):1220-1237. PubMed ID: 27916455
[TBL] [Abstract][Full Text] [Related]
11. Emerging biology of PDE10A.
Wilson LS; Brandon NJ
Curr Pharm Des; 2015; 21(3):378-88. PubMed ID: 25159072
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the striatal specific phosphodiesterase PDE10A ameliorates striatal and cortical pathology in R6/2 mouse model of Huntington's disease.
Giampà C; Laurenti D; Anzilotti S; Bernardi G; Menniti FS; Fusco FR
PLoS One; 2010 Oct; 5(10):e13417. PubMed ID: 20976216
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
[TBL] [Abstract][Full Text] [Related]
14. Chronic suppression of phosphodiesterase 10A alters striatal expression of genes responsible for neurotransmitter synthesis, neurotransmission, and signaling pathways implicated in Huntington's disease.
Kleiman RJ; Kimmel LH; Bove SE; Lanz TA; Harms JF; Romegialli A; Miller KS; Willis A; des Etages S; Kuhn M; Schmidt CJ
J Pharmacol Exp Ther; 2011 Jan; 336(1):64-76. PubMed ID: 20923867
[TBL] [Abstract][Full Text] [Related]
15. Phosphodiesterase 10A inhibitor, MP-10 (PF-2545920), produces greater induction of c-Fos in dopamine D2 neurons than in D1 neurons in the neostriatum.
Wilson JM; Ogden AM; Loomis S; Gilmour G; Baucum AJ; Belecky-Adams TL; Merchant KM
Neuropharmacology; 2015 Dec; 99():379-86. PubMed ID: 26256420
[TBL] [Abstract][Full Text] [Related]
16. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
Bernheimer H; Birkmayer W; Hornykiewicz O; Jellinger K; Seitelberger F
J Neurol Sci; 1973 Dec; 20(4):415-55. PubMed ID: 4272516
[No Abstract] [Full Text] [Related]
17. Phosphodiesterase 10A (PDE10A) localization in the R6/2 mouse model of Huntington's disease.
Leuti A; Laurenti D; Giampà C; Montagna E; Dato C; Anzilotti S; Melone MA; Bernardi G; Fusco FR
Neurobiol Dis; 2013 Apr; 52():104-16. PubMed ID: 23220622
[TBL] [Abstract][Full Text] [Related]
18. Patterns of age related changes for phosphodiesterase type-10A in comparison with dopamine D
Fazio P; Schain M; Mrzljak L; Amini N; Nag S; Al-Tawil N; Fitzer-Attas CJ; Bronzova J; Landwehrmeyer B; Sampaio C; Halldin C; Varrone A
Neuroimage; 2017 May; 152():330-339. PubMed ID: 28254508
[TBL] [Abstract][Full Text] [Related]
19. Serotonin modulation of the basal ganglia circuitry: therapeutic implication for Parkinson's disease and other motor disorders.
Di Matteo V; Pierucci M; Esposito E; Crescimanno G; Benigno A; Di Giovanni G
Prog Brain Res; 2008; 172():423-63. PubMed ID: 18772045
[TBL] [Abstract][Full Text] [Related]
20. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain.
Perry TL; Hansen S; Kloster M
N Engl J Med; 1973 Feb; 288(7):337-42. PubMed ID: 4345566
[No Abstract] [Full Text] [Related]
[Next] [New Search]
